Abstract
Immunosuppressive regimens for organ transplant recipients evolved from trial and error and drug-by-drug trials, with few prospective randomized comparisons of combination “a” vs. combination “b”. Unless treatment cohorts are equivalent, analyses of immunosuppressive drug studies in kidney transplantation have been skewed by inequity in study groups including: donor-recipient compatibility, sporadic induction with monoclonal antibody antilymphocyte products, timing and dose of corticosteroids, choice of one of four main immunosuppressive drugs (azathioprine, cyclosporine, tacrolimus, mycophenolate), subsequent dosage and frequency of selected drugs.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
White SA, Jain S, Williams ST, Doughman T, Hayes P, Murphy G, Veitch PS, Horsburgh T, Nicholson ML. Randomized trial comparing neoral and tacrolimus immunosuppression for recipients of renal transplants procured from different donor groups. Transplant Proc. 2000;32:600–602.
Morris-Stiff G, Ostrowski K, Balaji V, Moore R, Darby C, Lord R, Jurewicz WA. Prospective randomised study comparing tacrolimus (Prograf) and cyclosporin (Neoral) as primary immunosuppression in cadaveric renal transplants at a single institution: interim report of the first 80 cases. Transplant Int. 1998;11(Supplement l):S334–S336.
Knoll GA, Bell RC. Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. Br Med J. 1999;318:1104–1107.
Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Br Med J. 1999;319:1136.
Hauser IA, Neumayer HN. Tacrolimus and cyclosporine efficacy in high-risk kidney transplantation. European Multicentre Tacrolimus (FK506) Renal Study Group. Transplant Int. 1998;11(Supplement l):S73–S77.
Raofi V, Holman DM, Coady N, Vazquez E, Dunn TB, Bartholomew AM, Pollak R, Benedetti, E. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. Am J Surg. 1999;177:299–302.
Herrero JI, Quiroga J, Sangro B, Girala M, Gomez-Manero N, Pardo F, Alvarez-Cienfuegos J, Prieto J. Conversion of liver transplant recipients on cyclosporine with renal impairment to mycophenolate mofetil. Liver Transplant Surg. 1999;5:414–420.
Pirsch JD. Cytomegalovirus infection and post-transplant lymphoproliferative disease in renal transplant recipients: results of the U.S. Multicenter FK506 Kidney Transplant Study Group. Transplantation. 1999;68:1203–1205.
Plosker GL, Foster RH. Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation. Drug. 2000;59:323–389.
Johnson C, Ahsan N, Gonwa T, Halloran P, Stegall M, Hardy M, Metzger R, Shield C III, Rocher L, Scandling J, Sorensen J, Mulloy L, Light J, Corwin C, Danovitch G, Wachs M, van Veldhuisen P, Salm K, Tolzman D, Fitzsimmons WE. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation. 2000;69:834–841.
van Hooff JP, Christiaans MH. Use of tacrolimus in renal transplantation. Transplant Proc. 1999;31(8):3298–3299.
Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation. 1998;65:380–384.
Higgins RM, Hart P, Lam FT, Kashi H. Conversion from tacrolimus to cyclosporin in stable renal transplant patients: safety, metabolic changes, and pharmacokinetic comparison. Transplantation. 2000;69:1736–1739.
Ghasemian SR, Light JA, Currier C, Sasaki TM, Aquino A. Tacrolimus vs. neoral in renal and renal/pancreas transplantation. Clin Transplant. 1999;13(Pt 2):123–125.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Science+Business Media New York
About this chapter
Cite this chapter
Benyamine, M.G. (2002). Myth: Tacrolimus is superior to cyclosporine in renal transplantation. In: Friedman, E.A., Anees, I. (eds) Myths and Shibboleths in Nephrology. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-0407-7_13
Download citation
DOI: https://doi.org/10.1007/978-94-010-0407-7_13
Publisher Name: Springer, Dordrecht
Print ISBN: 978-1-4020-0616-6
Online ISBN: 978-94-010-0407-7
eBook Packages: Springer Book Archive